Loading clinical trials...
Loading clinical trials...
Applicability of Liver Transplantation in Alcoholic Hepatitis
Patients with alcoholic hepatitis non-responsive to steroids have a poor prognosis. Recently a French-Belgian prospective study has obtained good results (acceptable survival with a low rate of alcohol recidivism). The hypothesis of the present study is that carefully selected Spanish patients with alcoholic hepatitis that do not respond to steroid therapy may have a good survival if they receive a liver transplant. The expected rate of alcohol recidivism in such a selected population will be low.
This is a open prospective multicenter study. Nineteen liver transplant units in Spain will take part in it. Inclusion criteria for patients: 1. Diagnosis of alcoholic hepatitis (liver biopsy will be advisable). 2. First episode of clinical decompensation of alcoholic liver disease (defined as jaundice, variceal bleeding, ascites or portal-systemic encephalopathy). 3. Absence of a high risk of alcoholic recidivism (according to De Gottardi, et al). 4. Severe alcoholic hepatitis (ABIC score \> 6.71) 5. Informed consent Exclusion criteria : 1. Age over 65 years. 2. Hepatitis B or C or HIV infections. 3. Uncontrolled bacterial infection 4. Other liver diseases, such as alpha-1-antitrypsin deficiency, primary biliary cirrhosis, ... 5. Morbid obesity (BMI \> 35 kg/m2) 6. Major uncontrolled psychiatric disease 7. Drug addiction (excluding tobacco) in the last two years. 8. Absence of informed consent. 9. Acute-on-chronic liver disease. 10. Paracetamol consumption over 10 grams in the last week. Criteria for liver transplantation. 1. Absence of response to steroid therapy (Lille score ≥ 0.45 7 days after initiation of steroid therapy). 2. Adequate social and familiar environment. 3. Complete agreement in the medical staff about the candidate to transplantation. 4. Absence of bacterial or fungal infection. Three groups of patients will be formed: Group 1. Patients with severe alcoholic hepatitis and good response to therapy. Group 2. Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation. Group 3. Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation. A complete follow-up of the patients would be extended to five years. The survival of these three groups will be compared. Survival of liver transplant recipients should also be compared with survival of other liver transplant recipients. Alcohol recidivism should also be studied in all the patients of the study. Sample size estimation: According to the data published by Mathurin et al, 28 patients treated with liver transplantation and 28 non-transplanted patients with severe alcoholic hepatitis should be necessary. Interim analysis after every 10 transplanted patients should be performed. The study will be interrupted if the differences in the survivals between groups 2 and 3 reaches a significance of 0.01. In case this significance is not reached the inclusion of patients should end when 40 patients are transplanted. This sample size is estimated to be reached in 18-24 months.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Hospital Vall d'Hebrón
Barcelona, Barcelona, Spain
Hospital Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Reina Sofía
Córdoba, Córdoba, Spain
Hospital Virgen de la Nieves
Granada, Granada, Spain
Complejo Hospitalario Universitario de la Coruña
A Coruña, La Coruña, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, La Coruña, Spain
Hospital Gregorio Marañón
Madrid, Madrid, Spain
Hospital Ramón y Cajal
Madrid, Madrid, Spain
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Virgen de la Arrixaca
Murcia, Murcia, Spain
Start Date
January 1, 2013
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2017
Last Updated
June 3, 2014
40
ESTIMATED participants
Lead Sponsor
Sociedad Española de Trasplante Hepático
Collaborators
NCT06919458
NCT06956482
NCT03850899
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions